Trial intelligence / Profile preview

Early methotrexate step-up care versus early combination DMARD therapy versus early adalimumab-based therapy for psoriatic arthritis

2017-004542-24Phase 4Unknown

Sponsor
University of Oxford
Start
Jul 2018
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of methotrexate, 5-aminosalicylic acid + sulphasalazine, leflunomide and adalimumab in psoriatic arthritis (PsA) (3 arms), sponsored by University of Oxford. Primary endpoint: PASDAS good response at week 24. Status: unknown.

02

Drugs

methotrexate5-aminosalicylic acid + sulphasalazineleflunomideadalimumab
03

Conditions

psoriatic arthritis (PsA)

Beyond the preview

Go deeper on 2017-004542-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-004542-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call